YDES

TAIPEI, Taiwan, Aug. 25, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovations, today announced the publication of a peer-reviewed review article in Nutrients, an international open-access journal published by MDPI (Multidisciplinary Digital Publishing Institute). The article, titled "Beyond Bone Health: Exploring the ‘Heart–Brain–Bone’ Axis Modulated by Lipid-Soluble Nutrients (Omega-3, Vitamin D3, and Vitamin K2)," was co-authored by members of the Company’s scientific team together with physicians associated with the Taiwan Chronic Disease Healt

424B3 - YD Bio Ltd (0002011674) (Filer)

6-K - YD Bio Ltd (0002011674) (Filer)

Two chrono-nutrition formulations — a daytime lipid-soluble "Golden Triangle" formula and a nighttime zinc-plus-calcium formula — were developed in collaboration with the Taiwan CDHA and FHI. The Company intends to expand this approach by exploring additional opportunities for collaboration with other physicians and healthcare organizations. TAIPEI, Taiwan, Aug. 11, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovations, today announced its initial step towards building a physician-partnership ecosystem and related consumer health commercialization

Published in Bioengineering, a collaborative study with Taipei Medical University researchers identifies key molecular candidates to help guide the development of regenerative therapies for corneal disease. TAIPEI, Taiwan, Aug. 04, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovations, today highlighted the publication of a new peer-reviewed study in the journal Bioengineering, published by Multidisciplinary Digital Publishing Institute. Co-authored by YD Bio scientists and physician-researchers from Taipei Medical University ("TMU") and Taipei Me

The six-month pilot is designed to evaluate the potential scalability of bringing physician-ordered, blood-based OkaiDx laboratory-developed tests to patients in Canada Taipei, Taiwan, July 28, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovations, today announced the launch of a six-month pilot collaboration (the "Pilot") pursuant to that certain Pilot Service Agreement, dated as of July 23, 2026 (the "Agreement"), by and among YD Bio, YD Bio US Inc., a subsidiary of YD Bio ("YD Bio US"), EG BioMed US Inc., an affiliate of YD Bio ("EG BioMed US")

Taipei, Taiwan, July 23, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced the successful conclusion of YD Bio’s and its affiliate EG BioMed Co., Ltd.’s ("EG BioMed") participation at BIO Asia-Taiwan 2026, an international industry conference held in Taiwan, at the Washington State Pavilion on July 19, 2026. The companies showcased their advancements and offerings across: ophthalmic regenerative medicine, DNA-based cancer detection, and U.S. market entry services for life science partners. Advancements in Ophthalmology: Commer

Taipei, Taiwan, July 02, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovations, today announced that its affiliate, EG BioMed US Inc., a Delaware corporation ("EG BioMed US"), has obtained out-of-state clinical laboratory licenses in Rhode Island and Pennsylvania for its CLIA-certified, CAP-accredited laboratory in Bothell, Washington (CLIA #50D2316600), reinforcing the Company’s transition from a collection of technologies to a platform-based biotechnology company anchored in clinically derived molecular data. The Rhode Island license, issued May

4 - YD Bio Ltd (0002011674) (Issuer)

4 - YD Bio Ltd (0002011674) (Issuer)

EFFECT - YD Bio Ltd (0002011674) (Filer)

POS AM - YD Bio Ltd (0002011674) (Filer)

TAIPEI, Taiwan, April 30, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced its financial results for the full year ended December 31, 2025. Management Commentary"2025 was a highly transformative and foundational year for YD Bio, characterized by the successful capitalization of our long-term strategic vision. The successful completion of our business combination with Breeze Holdings Acquisition Corp. in August 2025, alongside a $13.2 million private investment in public equity (PIPE) financing, helped to significantly strengt

20-F - YD Bio Ltd (0002011674) (Filer)

3/A - YD Bio Ltd (0002011674) (Issuer)

4 - YD Bio Ltd (0002011674) (Issuer)

4 - YD Bio Ltd (0002011674) (Issuer)

3 - YD Bio Ltd (0002011674) (Issuer)

3 - YD Bio Ltd (0002011674) (Issuer)

Taipei, Taiwan, March 31, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company and EG BioMed Co., Ltd., a Taiwan registered company ("EG BioMed"), officially launched the EG Telehealth Platform, https://mdi.eg-bio.com, which marks a significant milestone in the Company's commercialization of early cancer detection and decentralized clinical service delivery across the United States. The platform is now live and enables access across 44 U.S. states, plus Washington, D.C. and Guam, supported by a nationwide network

3 - YD Bio Ltd (0002011674) (Issuer)

3 - YD Bio Ltd (0002011674) (Issuer)

3 - YD Bio Ltd (0002011674) (Issuer)

3 - YD Bio Ltd (0002011674) (Issuer)

Taipei, Taiwan, March 17, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio Ltd" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today highlighted the strategic roadmap shared by CEO Dr. Ethan Shen in a recent interview with PharmaBoardroom, a UK-based platform providing insights to the global healthcare and life sciences community. Moving beyond the traditional single-asset biotech model, YD Bio Ltd is building a comprehensive ecosystem that synchronizes diagnostic intelligence with advanced therapeutic execution. In the interview, Dr. Shen addressed the Company's approach to the biotech